Gynecological Endocrinology · 2017 · 19 citations · 22 references
MedicineGynecologyObstetricsIn Vitro FertilizationReproductive EndocrinologyReproductive MedicineHormonal EvaluationLuteal Phase SupportProgesterone TherapyDose Adjustment AssessmentDose Adjustment CriteriaLive Birth Outcome AssessmentOocyte In Vitro FertilizationPregnancy Outcome AssessmentProgesterone Dosing RegimensSerum Progesterone MonitoringSupplement Dosage
Our study aimed to determine whether mid-luteal serum P concentrations can serve as a predictive factor for in vitro fertilization (IVF) outcomes and whether increasing P dosage for patients with low levels at mid-luteal phase may improve pregnancy rates. It was a prospective, randomized controlled study. A total of 146 patients undergoing IVF treatment were prospectively enrolled and received routine luteal phase support (LPS) regimen of Endometrin® (progesterone) 200 mg/day. Serum P levels were measured 7 days after embryo transfer (ET). Considering a cutoff level of 15 ng/ml on this day, patients with higher levels continued the same dosage until pregnancy test (control group). Patients with lower levels were randomly allocated to continue Endometrin® 200 mg/day (Group A) or to increase Endometrin® dosage to 300 mg/day (Group B). The Main Outcome Measures were pregnancy rates. Both biochemical and clinical pregnancy and live birth rates were comparable between all groups regardless of P level on day 7 of luteal phase and regardless of dose adjustment. ROC analysis determined that mid-luteal P levels of 17 ng/ml can be a better predictor of cycle outcome. In conclusion raising the P dose at mid-luteal phase to 300 mg daily did not improve cycle outcomes.
22
The window of embryo transfer and the efficiency of human conception in vitro
Daniel Navot, Richard T. Scott, Kathleen Droesch et al. · Fertility and Sterility · 1991 · 305 citations
Medicine, Gynecology, Obstetrics +13
Human Reproduction · 1998 · 293 citations · Full text